Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.10
A's Cash to Debt is ranked higher than
62% of the 258 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.79 vs. A: 1.10 )
A' s 10-Year Cash to Debt Range
Min: 0.67   Max: No Debt
Current: 1.1

Equity to Asset 0.49
A's Equity to Asset is ranked higher than
62% of the 240 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.64 vs. A: 0.49 )
A' s 10-Year Equity to Asset Range
Min: 0.33   Max: 0.71
Current: 0.49

0.33
0.71
Interest Coverage 7.35
A's Interest Coverage is ranked higher than
54% of the 146 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.48 vs. A: 7.35 )
A' s 10-Year Interest Coverage Range
Min: 0.53   Max: 9999.99
Current: 7.35

0.53
9999.99
F-Score: 5
Z-Score: 3.63
M-Score: -2.50
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 11.90
A's Operating margin (%) is ranked higher than
88% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.61 vs. A: 11.90 )
A' s 10-Year Operating margin (%) Range
Min: -26.74   Max: 16.32
Current: 11.9

-26.74
16.32
Net-margin (%) 7.12
A's Net-margin (%) is ranked higher than
85% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.20 vs. A: 7.12 )
A' s 10-Year Net-margin (%) Range
Min: -46.06   Max: 66.5
Current: 7.12

-46.06
66.5
ROE (%) 9.11
A's ROE (%) is ranked higher than
81% of the 232 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.08 vs. A: 9.11 )
A' s 10-Year ROE (%) Range
Min: -55.24   Max: 85.57
Current: 9.11

-55.24
85.57
ROA (%) 4.65
A's ROA (%) is ranked higher than
82% of the 260 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. A: 4.65 )
A' s 10-Year ROA (%) Range
Min: -28.39   Max: 46.84
Current: 4.65

-28.39
46.84
ROC (Joel Greenblatt) (%) 43.64
A's ROC (Joel Greenblatt) (%) is ranked higher than
89% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.02 vs. A: 43.64 )
A' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -54.39   Max: 71.3
Current: 43.64

-54.39
71.3
Revenue Growth (%) 3.50
A's Revenue Growth (%) is ranked higher than
73% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. A: 3.50 )
A' s 10-Year Revenue Growth (%) Range
Min: -22.8   Max: 18.4
Current: 3.5

-22.8
18.4
EBITDA Growth (%) -4.30
A's EBITDA Growth (%) is ranked higher than
70% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. A: -4.30 )
A' s 10-Year EBITDA Growth (%) Range
Min: -27.7   Max: 76.8
Current: -4.3

-27.7
76.8
EPS Growth (%) -19.80
A's EPS Growth (%) is ranked higher than
65% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.30 vs. A: -19.80 )
A' s 10-Year EPS Growth (%) Range
Min: -19.8   Max: 135.6
Current: -19.8

-19.8
135.6
» A's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

A Guru Trades in Q4 2013

Jim Simons 276,700 sh (New)
Caxton Associates 43,510 sh (New)
John Hussman 313,000 sh (+99.36%)
George Soros 17,500 sh (unchged)
Ron Baron 26,000 sh (unchged)
Caxton Associates 60,000 sh (unchged)
George Soros 24,425 sh (unchged)
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
Sarah Ketterer Sold Out
PRIMECAP Management 94,609 sh (-0.11%)
Chris Davis 3,585,021 sh (-1.11%)
Vanguard Health Care Fund 5,624,200 sh (-4.66%)
Pioneer Investments 108,367 sh (-5.69%)
Richard Snow 1,204,695 sh (-8.48%)
Robert Olstein 85,000 sh (-32%)
Brian Rogers 1,497,454 sh (-33.45%)
David Dreman 550 sh (-72.38%)
Steven Cohen 45,324 sh (-80.64%)
» More
Q1 2014

A Guru Trades in Q1 2014

Paul Tudor Jones 6,156 sh (New)
Signature Select Canadian Fund 191,600 sh (New)
David Dreman 2,134 sh (+288%)
Steven Cohen 128,546 sh (+183.62%)
Ron Baron 26,000 sh (unchged)
John Hussman 313,000 sh (unchged)
Caxton Associates 60,000 sh (unchged)
Vanguard Health Care Fund 5,624,200 sh (unchged)
Brian Rogers Sold Out
Jim Simons Sold Out
George Soros Sold Out
Pioneer Investments Sold Out
Caxton Associates Sold Out
Robert Olstein Sold Out
PRIMECAP Management 94,009 sh (-0.63%)
Chris Davis 3,246,884 sh (-9.43%)
Richard Snow 649,036 sh (-46.12%)
» More
Q2 2014

A Guru Trades in Q2 2014

Jean-Marie Eveillard 831,224 sh (New)
John Keeley 46,640 sh (New)
Paul Tudor Jones 128,579 sh (+1988.68%)
David Dreman 2,332 sh (+9.28%)
Ron Baron 26,000 sh (unchged)
Vanguard Health Care Fund 5,624,200 sh (unchged)
John Hussman Sold Out
Richard Snow Sold Out
PRIMECAP Management 91,717 sh (-2.44%)
Chris Davis 2,991,923 sh (-7.85%)
» More
Q3 2014

A Guru Trades in Q3 2014

Jim Simons 187,500 sh (New)
John Burbank 35,000 sh (New)
Joel Greenblatt 372,199 sh (New)
PRIMECAP Management 2,813,589 sh (+2967.69%)
Paul Tudor Jones 209,138 sh (+62.65%)
Jean-Marie Eveillard 1,129,300 sh (+35.86%)
Signature Select Canadian Fund 257,600 sh (+34.45%)
John Keeley 48,840 sh (+4.72%)
David Dreman 2,411 sh (+3.39%)
Ron Baron 26,000 sh (unchged)
Vanguard Health Care Fund 5,624,200 sh (unchged)
Chris Davis 2,980,262 sh (-0.39%)
» More
» Details

Insider Trades

Latest Guru Trades with A

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-09-30 New Buy0.21%$38.858 - $42.111 $ 40.70%372199
PRIMECAP Management 2014-09-30 Add 2967.69%0.16%$38.858 - $42.111 $ 40.70%2813589
Jean-Marie Eveillard 2014-09-30 Add 35.86%0.04%$38.858 - $42.111 $ 40.70%1129300
John Burbank 2014-09-30 New Buy0.03%$38.858 - $42.111 $ 40.70%35000
Richard Snow 2014-06-30 Sold Out 1.4%$37.66 - $42.4 $ 40.71%0
John Hussman 2014-06-30 Sold Out 1.3%$37.66 - $42.4 $ 40.71%0
Jean-Marie Eveillard 2014-06-30 New Buy0.12%$37.66 - $42.4 $ 40.71%831224
John Keeley 2014-06-30 New Buy0.05%$37.66 - $42.4 $ 40.71%46640
Richard Snow 2014-03-31 Reduce -46.12%1.29%$39.12 - $43.58 $ 40.7-1%649036
Robert Olstein 2014-03-31 Sold Out 0.7%$39.12 - $43.58 $ 40.7-1%0
Brian Rogers 2014-03-31 Sold Out 0.31%$39.12 - $43.58 $ 40.7-1%0
George Soros 2014-03-31 Sold Out 0.01%$39.12 - $43.58 $ 40.7-1%0
David Dreman 2014-03-31 Add 288%0.01%$39.12 - $43.58 $ 40.7-1%2134
John Hussman 2013-12-31 Add 99.36%0.65%$35.73 - $41.41 $ 40.77%313000
Robert Olstein 2013-12-31 Reduce -32%0.31%$35.73 - $41.41 $ 40.77%85000
Richard Snow 2013-12-31 Reduce -8.48%0.25%$35.73 - $41.41 $ 40.77%1204695
Brian Rogers 2013-12-31 Reduce -33.45%0.15%$35.73 - $41.41 $ 40.77%1497454
Joel Greenblatt 2013-12-31 Sold Out 0.04%$35.73 - $41.41 $ 40.77%0
David Dreman 2013-12-31 Reduce -72.38%0.01%$35.73 - $41.41 $ 40.77%550
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 28.10
A's P/E(ttm) is ranked higher than
88% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. A: 28.10 )
A' s 10-Year P/E(ttm) Range
Min: 2.74   Max: 48.25
Current: 28.1

2.74
48.25
P/B 2.60
A's P/B is ranked higher than
82% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.37 vs. A: 2.60 )
A' s 10-Year P/B Range
Min: 1.21   Max: 3.92
Current: 2.6

1.21
3.92
P/S 2.00
A's P/S is ranked higher than
82% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.06 vs. A: 2.00 )
A' s 10-Year P/S Range
Min: 0.59   Max: 3.9
Current: 2

0.59
3.9
PFCF 27.50
A's PFCF is ranked higher than
86% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. A: 27.50 )
A' s 10-Year PFCF Range
Min: 5.38   Max: 72.59
Current: 27.5

5.38
72.59
EV-to-EBIT 16.15
A's EV-to-EBIT is ranked higher than
89% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. A: 16.15 )
A' s 10-Year EV-to-EBIT Range
Min: -143.5   Max: 305.7
Current: 16.15

-143.5
305.7
PEG 7.15
A's PEG is ranked higher than
88% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. A: 7.15 )
A' s 10-Year PEG Range
Min: 0.08   Max: 7.44
Current: 7.15

0.08
7.44
Shiller P/E 20.90
A's Shiller P/E is ranked higher than
97% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. A: 20.90 )
A' s 10-Year Shiller P/E Range
Min: 6.42   Max: 87.11
Current: 20.9

6.42
87.11
Current Ratio 3.31
A's Current Ratio is ranked higher than
77% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.56 vs. A: 3.31 )
A' s 10-Year Current Ratio Range
Min: 1.92   Max: 3.53
Current: 3.31

1.92
3.53
Quick Ratio 2.66
A's Quick Ratio is ranked higher than
76% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. A: 2.66 )
A' s 10-Year Quick Ratio Range
Min: 0.99   Max: 3.04
Current: 2.66

0.99
3.04

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.30
A's Dividend Yield is ranked higher than
53% of the 79 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.31 vs. A: 1.30 )
A' s 10-Year Dividend Yield Range
Min: 0.31   Max: 1.42
Current: 1.3

0.31
1.42
Dividend Payout 0.25
A's Dividend Payout is ranked higher than
93% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. A: 0.25 )
A' s 10-Year Dividend Payout Range
Min: 0.09   Max: 0.36
Current: 0.25

0.09
0.36
Yield on cost (5-Year) 1.30
A's Yield on cost (5-Year) is ranked lower than
57% of the 81 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. A: 1.30 )
A' s 10-Year Yield on cost (5-Year) Range
Min: 0.31   Max: 1.42
Current: 1.3

0.31
1.42
Share Buyback Rate 1.60
A's Share Buyback Rate is ranked higher than
94% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.60 vs. A: 1.60 )
A' s 10-Year Share Buyback Rate Range
Min: 9.5   Max: -7
Current: 1.6

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 8.00
A's Price/Tangible Book is ranked higher than
70% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.74 vs. A: 8.00 )
A' s 10-Year Price/Tangible Book Range
Min: 1.1   Max: 10.49
Current: 8

1.1
10.49
Price/DCF (Projected) 0.90
A's Price/DCF (Projected) is ranked higher than
98% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. A: 0.90 )
A' s 10-Year Price/DCF (Projected) Range
Min: 0.65   Max: 2.75
Current: 0.9

0.65
2.75
Price/Median PS Value 1.10
A's Price/Median PS Value is ranked higher than
78% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.32 vs. A: 1.10 )
A' s 10-Year Price/Median PS Value Range
Min: 0.4   Max: 1.28
Current: 1.1

0.4
1.28
Price/Peter Lynch Fair Value 1.50
A's Price/Peter Lynch Fair Value is ranked higher than
96% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. A: 1.50 )
A' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.46   Max: 1.57
Current: 1.5

0.46
1.57
Price/Graham Number 3.10
A's Price/Graham Number is ranked higher than
87% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. A: 3.10 )
A' s 10-Year Price/Graham Number Range
Min: 0.97   Max: 3.97
Current: 3.1

0.97
3.97
Earnings Yield (Greenblatt) 6.20
A's Earnings Yield (Greenblatt) is ranked higher than
89% of the 253 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. A: 6.20 )
A' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 17.1
Current: 6.2

0.3
17.1
Forward Rate of Return (Yacktman) 24.82
A's Forward Rate of Return (Yacktman) is ranked higher than
93% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.35 vs. A: 24.82 )
A' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -0.8   Max: 78.6
Current: 24.82

-0.8
78.6

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:ROP, GRMN, HXGBY, TRMB, NANO » details
Traded in other countries:AG8.Germany,
Agilent Technologies Inc was incorporated in Delaware in May 1999. The Company is a measurement company, providing core bio-analytical and electronic measurement solutions to the life sciences, chemical analysis, communications and electronics industries. The four operating segments are Life sciences business, Chemical Analysis Business, Diagnostics and Genomics Business and Electronic Measurement Business. Life sciences business provides application-focused solutions that include instruments, software, consumables, and services that enable customers to identify, quantify and analyze the physical and biological properties of substances and products. Key product categories in life sciences include: liquid chromatography systems, columns and components; liquid chromatography mass spectrometry systems; laboratory software and informatics systems; laboratory automation and robotic systems; dissolution testing; nucleic acid solutions; Nuclear Magnetic Resonance ; Magnetic Resonance Imaging and X-Ray Diffraction systems and services and support for the aforementioned products. The Chemical Analysis business provides application-focused solutions that include instruments, software, consumables, and services that enable customers to identify, quantify and analyze the physical and biological properties of substances and products. Key product categories in chemical analysis include: gas chromatography systems, columns and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; software and data systems; vacuum pumps and measurement technologies; services and support for its products. Diagnostics and genomics business provides solutions that include reagents, instruments, software and consumables that enable customers in the clinical and life sciences research areas to interrogate samples at the molecular level. Its offerings include immunohistochemistry, In Situ Hybridization, Hematoxylin and Eosin Staining, special staining, DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, as well as automated gel electrophoresis-based sample analysis systems. Electronic Measurement Business provides electronic measurement instruments and systems, software design tools and related services that are used in the design, development, manufacture, installation, deployment and operation of electronics equipment, and microscopy products. Related services include start-up assistance, instrument productivity and application services and instrument calibration and repair. The Company's primary competitors are Bruker Corp., Danaher Corporation, Thermo Fisher Scientific Inc., Waters Corp, PerkinElmer Inc., Shimadzu Corporation, Ventana Medi
» More Articles for A

Headlines

Articles On GuruFocus.com
Agilent Has Focused on Several Strategic Actions Mar 20 2014 
Chris Davis' Davis Funds 2013 Portfolio Managers Update Feb 27 2014 
$500 Billion Manager Brian Rogers’ About-Face on Apple Inc. Dec 02 2013 
The Best Yielding Ex-Dividend Stocks on March 28, 2013 Mar 27 2013 
comment on A Mar 15 2013 
comment on A Mar 15 2013 
Edward Owens’ 3 Biggest Stock Increases Feb 05 2013 
My 4 Favorites of the 32 Stocks with Dividend Growth from Last Week Jan 20 2013 
comment on A Sep 20 2012 
Value Investor Robert Olstein: Market Is Overreacting and His Top Picks Aug 10 2012 

More From Other Websites
Agilent’s Evolution Since Spinoff May Lead to Takeover: Real M&A Dec 17 2014
Repsol to Acquire Talisman Energy for US$8.00 Per Common Share Dec 17 2014
Nine-Year-Old's Arrest Prompts Call for Change by Federal Judge Dec 05 2014
Agilent Technologies and Baylor College of Medicine Open Center of Excellence in Mass Spectrometry Dec 04 2014
Electronic Arts Inc. (EA) Rises: Stock Adds 5.4% in Session Dec 04 2014
Boston Properties to Participate in the UBS 2014 Global Real Estate CEO/CFO Conference Dec 01 2014
Analysts' Actions: Agilent Technologies, Biglari Holdings Dec 01 2014
Rambus to Present at the NASDAQ OMX 31st Investor Program Nov 26 2014
Agilent Technologies Names Patrick Kaltenbach, Jacob Thaysen Business Group Presidents; New... Nov 24 2014
Why Agilent Technologies (A) Could Be Positioned for a Slump Nov 21 2014
Agilent Technologies Announces Cash Dividend of 10 Cents per Share Nov 20 2014
Agilent Technologies Announces Cash Dividend of 10 Cents per Share Nov 20 2014
Agilent Technologies Names Patrick Kaltenbach, Jacob Thaysen Business Group Presidents; New... Nov 20 2014
Autohome (ATHM) Stock Lower Today After Follow-On Public Offering Nov 20 2014
Agilent Technologies Introduces Portable FTIR Package to Identify Polymers, Measure Total Phthalates Nov 19 2014
Agilent Beats on Q4 Earnings, Guides Above Expectations Nov 19 2014
Agilent Technologies (A) Earnings Report: Q4 2014 Conference Call Transcript Nov 18 2014
Agilent Technologies Conference Call Highlights Nov 18 2014
Why Scotch whisky is worth protecting Nov 18 2014
Agilent Technologies (A) Stock Sinks Today on Earnings Slip Nov 18 2014
Agilent Technologies Inc Earnings Call scheduled for 5:30 pm ET today Nov 17 2014
Agilent Technologies Reports Narrow EPS Miss Nov 17 2014
Agilent earnings slip, but sales rise from a year ago Nov 17 2014
Agilent beats 4Q profit forecasts Nov 17 2014
Agilent beats 4Q profit forecasts Nov 17 2014
AGILENT TECHNOLOGIES INC Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 17 2014
Agilent Technologies Reports Fourth-Quarter 2014 Results Nov 17 2014
What to Expect From Agilent Technologies (A) Earnings Today Nov 17 2014
Ford may be a buy, but U.S. stocks look stretched vs. the rest of the world Nov 17 2014
Agilent Technologies Introduces New Column Innovations for Biotherapeutics Development Nov 11 2014
Assured Guaranty Ltd. Reports Results for Third Quarter 2014 Nov 06 2014
Agilent Technologies Advances FTIR Microscopy Imaging Nov 06 2014
Agilent Technologies Granted Dismissal in Patent Infringement Suit Brought by Genetic Technologies Nov 03 2014
Agilent Technologies Granted Dismissal in Patent Infringement Suit Brought by Genetic Technologies Nov 03 2014
Agilent Technologies Spins Off Its Electronic Measurement Business, Keysight Technologies Nov 03 2014
Agilent Technologies to Host Webcast of Fourth-Quarter Fiscal Year 2014 Financial Results Conference... Oct 31 2014
Agilent Technologies Introduces Powerful Enhancements to Leading Life Science Software Oct 29 2014
TRADE NEWS: Keysight Technologies Supports B4G/5G Technology Development at National Taiwan... Oct 24 2014
THIRD QUARTER RESULTS CONFERENCE CALL AND WEBCAST DETAILS Oct 22 2014
Agilent Technologies Introduces miRNA Microarrays Featuring Latest miRBase 21 Content Oct 21 2014
Agilent Technologies Introduces Focused Exome Kit with Unparalleled Coverage, Speed, Flexibility for... Oct 20 2014
Agilent Technologies Introduces Cutting-Edge Accessories to Support LC Workflows Oct 17 2014
Agilent Technologies to Close Nuclear Magnetic Resonance Business Oct 14 2014
Agilent Technologies to Close Nuclear Magnetic Resonance Business Oct 14 2014
All 10 Episodes of the Critically Acclaimed Dark Comedy Series Transparent Are Now Available on... Sep 26 2014
Xenetic Biosciences to Hold Business Update Conference Call September 23 at 6:00 a.m. Eastern Time Sep 22 2014
Agilent Technologies Announces CEO Transition: Mike McMullen to Succeed Bill Sullivan in March 2015 Sep 17 2014
Agilent Technologies Announces CEO Transition: Mike McMullen to Succeed Bill Sullivan in March 2015 Sep 17 2014
TRADE NEWS: Agilent Technologies to Introduce Next-Generation UHPLC System at Analytica China on... Sep 11 2014
TRADE NEWS: Keysight Technologies Joins 5G Forum in South Korea Aug 11 2014
TRADE NEWS: Agilent Technologies and China Mobile to Collaborate on Next-Generation 5G Wireless... Jun 24 2014
TRADE NEWS: Agilent Technologies Announces Collaboration with Nippon Avionics to Develop Enhanced... Jun 09 2014
China: U.S. cyber spying accusations 'made up' and will damage trust May 19 2014
Bayer first-quarter core profit beats consensus on strong pharma Apr 28 2014
Banks to return 6 billion euros in crisis loans to ECB next week Apr 14 2014
ECB sends former board member Hamalainen to new banking watchdog Mar 07 2014
Bitcoin true believers unfazed by losses in Mt. Gox collapse Mar 06 2014
China shares sink as a corporate bond default looms Mar 05 2014
Austrian banks won't support Hypo Alpe Adria 'bad bank': finance minister Feb 10 2014
Nissan - willing to sacrifice share target to ensure profitability Feb 10 2014
IATA says cargo is biggest worry for airlines Feb 09 2014
Microsoft's journey: four decades, three CEOs Feb 04 2014
Timeline: Microsoft's journey: four decades, three CEOs Feb 04 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK